ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Registration Strip Icon for default Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.
Intesity Therapeutics Inc

Intesity Therapeutics Inc (INTS)

2,43
0,20
( 8,97% )
Aktualisiert: 14:46:24

Professionelle Tools für Privatanleger.

Wichtige Statistiken und Details

Current Price
2,43
Gebot
2,20
Fragen
2,43
Volumen
1.410
2,17 Tagesbereich 2,43
1,50 52-Wochen-Bereich 5,78
Marktkapitalisierung
Handelsende
2,23
Handelsbeginn
2,17
Letzte Trade
100
@
2.43
Letzter Handelszeitpunkt
14:37:22
Finanzvolumen
US$ 3.115
VWAP
2,2089
Durchschnittliches Volumen (3 Mio.)
33.180
Ausgegebene Aktien
13.867.697
Dividendenrendite
-
Kurs-Gewinn-Verhältnis
-2,61
Gewinn pro Aktie (EPS)
-0,86
Erlöse
-
Nettogewinn
-11,86M

Über Intesity Therapeutics Inc

Intensity Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing an approach to treat solid tumor cancers. It leverages its DfuseRx technology platform to create proprietary drug formulations. Its product candidates have the potential to induce an adaptive... Intensity Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing an approach to treat solid tumor cancers. It leverages its DfuseRx technology platform to create proprietary drug formulations. Its product candidates have the potential to induce an adaptive immune response that attacks the injected and non-injected tumors. The Company's lead product candidate, INT230-6, is in development for the treatment of patients with solid tumors, such as sarcoma and breast cancer patients. The Company, through Merck Sharpe & Dohme (Merck), evaluates INT230-6 with pembrolizumab. In addition, it also evaluates the combination INT230-6 with Bristol-Myers Squibb's anti-CTLA-4 antibody, ipilimumab. It also has an agreement with the Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research to study INT230-6 in a randomized controlled neoadjuvant phase II study in women with early-stage breast cancer (the INVINCIBLE study) (NCT04781725). Mehr anzeigen

Sektor
Biological Pds,ex Diagnstics
Branche
Biological Pds,ex Diagnstics
Hauptsitz
Wilmington, Delaware, USA
Gegründet
-
Intesity Therapeutics Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker INTS. The last closing price for Intesity Therapeutics was US$2,23. Over the last year, Intesity Therapeutics shares have traded in a share price range of US$ 1,50 to US$ 5,78.

Intesity Therapeutics currently has 13.867.697 shares in issue. The market capitalisation of Intesity Therapeutics is US$30,92 million. Intesity Therapeutics has a price to earnings ratio (PE ratio) of -2.61.

INTS Neueste Nachrichten

Zeitraum †ÄnderungÄnderung %HandelsbeginnHochNiedrigDurchsch. VolumenVWAP
10.14.291845493562.332.432.17217562.2531738CS
40.072.966101694922.362.48161.84220422.1945996CS
120.419.70443349752.033.16631.5331802.21552754CS
26-1.72-41.44578313254.154.321.5267412.52909633CS
52-2.8-53.53728489485.235.781.5215993.37143311CS
156-3.52-59.15966386555.9511.441.51166086.34491321CS
260-3.52-59.15966386555.9511.441.51166086.34491321CS

INTS - Frequently Asked Questions (FAQ)

What is the current Intesity Therapeutics share price?
The current share price of Intesity Therapeutics is US$ 2,43
How many Intesity Therapeutics shares are in issue?
Intesity Therapeutics has 13.867.697 shares in issue
What is the market cap of Intesity Therapeutics?
The market capitalisation of Intesity Therapeutics is USD 30,92M
What is the 1 year trading range for Intesity Therapeutics share price?
Intesity Therapeutics has traded in the range of US$ 1,50 to US$ 5,78 during the past year
What is the PE ratio of Intesity Therapeutics?
The price to earnings ratio of Intesity Therapeutics is -2,61
What is the reporting currency for Intesity Therapeutics?
Intesity Therapeutics reports financial results in USD
What is the latest annual profit for Intesity Therapeutics?
The latest annual profit of Intesity Therapeutics is USD -11,86M
What is the registered address of Intesity Therapeutics?
The registered address for Intesity Therapeutics is 251 LITTLE FALLS DRIVE, WILMINGTON, DELAWARE, 19808
Which industry sector does Intesity Therapeutics operate in?
Intesity Therapeutics operates in the BIOLOGICAL PDS,EX DIAGNSTICS sector
  • Volumen
  • % Tops
  • % Flops
SymbolPreisVol.
SYRSSyros Pharmaceuticals Inc
US$ 0,202
(120,52%)
195,94M
TSVT2seventy bio Inc
US$ 4,925
(75,89%)
10,23M
AWHAspira Womans Health Inc
US$ 0,3165
(59,85%)
127,15M
CUTRCutera Inc
US$ 0,1992
(55,02%)
81,05M
ONDSOndas Holdings Inc
US$ 1,078
(48,28%)
41,55M
ARVNArvinas Inc
US$ 9,74
(-44,53%)
2,79M
EWCZEuropean Wax Center Inc
US$ 3,00
(-41,29%)
25,8k
LZMHLZ Technology Holdings Ltd
US$ 10,65
(-31,99%)
55,18k
SPGCSacks Parente Golf Inc
US$ 0,1101
(-31,23%)
15,74M
ELTKEltek Ltd
US$ 8,54
(-21,69%)
50,82k
SYRSSyros Pharmaceuticals Inc
US$ 0,20135
(119,81%)
188,92M
AWHAspira Womans Health Inc
US$ 0,3197
(61,46%)
125,17M
CUTRCutera Inc
US$ 0,199
(54,86%)
79,91M
TSLLDirexion Daily TSLA Bull 2X Trust ETF
US$ 7,96
(7,86%)
62,37M
BHATBlue Hat Interactive Entertainment Technology
US$ 0,037
(10,45%)
59,82M
Keine Diskussionen Gefunden.
Neuen Thread Erstellen

Kürzlich von Ihnen besucht

Delayed Upgrade Clock